Madrigal Pharmaceuticals, Inc. Stock

$315.46

0.26% day before yesterday

Nasdaq, Jul 11, 10:00 pm CET

ISIN

US5588681057

Symbol

MDGL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Madrigal Pharmaceuticals, Inc. Stock price

$315.46

+215.68 216.16% 5Y

Nasdaq, Closing price Fri, Jul 11 2025

+0.82 0.26%

ISIN

US5588681057

Symbol

MDGL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$7.0b

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | negative

P/S

22.1 | 10.1

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

72.4%

Return on Equity

-61.8%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$317.4m | $695.6m

EBITDA

$-423.8m | $-392.0m

EBIT

$-425.1m | $-341.6m

Net Income

$-391.6m | -

Free Cash Flow

$-401.4m

EPS

$-17.7

FCF per Share

Short interest

21.7%

Employees

528

Rev per Employee

$340.0k

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Madrigal Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

??

22 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

19x Buy

86%

More details on Analyst Estimates Including Price Targets

22 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast:

Buy

86%

Hold

Sell

Analyst Estimates with Stock Price Targets

Financial data from Madrigal Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	317 317	- 100%
- Direct Costs	11 11	- 3%
Gross Profit	307 307	- 97%
- Selling and Administrative Expenses	522 522	202% 202% 165%
- Research and Development Expense	210 210	26% 26% 66%
EBITDA	-424 -424	7% 7% -134%
- Depreciation and Amortization	1.31 1.31	126% 126% 0%
EBIT (Operating Income) EBIT	-425 -425	6% 6% -134%
Net Profit	-392 -392	12% 12% -123%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Madrigal Pharmaceuticals, Inc. Stock News

Positive

Market Watch

●

23 days ago

Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease noncirrhotic MASH who have moderate to advanced fibrosis.

Neutral

GlobeNewsWire

●

23 days ago

Madrigal Receives Positive CHMP Opinion for Resmetirom (Rezdiffra™) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

CONSHOHOCKEN, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending appro...

Neutral

GlobeNewsWire

●

26 days ago

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2025 to 36 new non-executive employees as equity inducement awards under the terms of Madrigal's 2023 Induceme...

More Madrigal Pharmaceuticals, Inc. News

Company Profile

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Head office	United States
CEO	William Sibold
Employees	528
Founded	2011
Website	www.madrigalpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now